EMulate Therapeutics, Inc. has announced that the Open Journal of Biophysics (OJBIPHY) will publish its manuscript, titled “Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice.” This study supports independent findings recently reported by Mukthavaram et al. (Bioelectron Med 2024 Vol. 10 Issue 1 Pages 10) and demonstrates the efficacy of EMulate’s A2 treatment in a mouse model of Glioblastoma Multiforme (GBM). GBM is a rare, aggressive brain tumor with no established treatment, classified by the FDA as a highly underserved orphan disease, affecting fewer than 200,000 individuals in the U.S.
The paper highlights how EMulate’s A2 signal treatment targets key immune checkpoint inhibitors CTLA-4 and PD-1, effectively reducing their expression and inhibiting tumor growth in a validated mouse model of Glioblastoma Multiforme (GBM). These findings align with the outcomes of a Phase I clinical trial (NCT02507102), which indicated the treatment’s safety and potential efficacy in humans.
Dr. Xavier Figueroa, SVP of Pre-Clinical Development at EMulate Therapeutics, remarked, “This pre-clinical study underscores the promise of our ulRFE technology in treating cancers and other diseases with significant unmet needs. We are optimistic about its potential benefits for patients with these genetic targets and look forward to validating these results in future clinical trials.”
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical-stage company specializing in radio frequency energy technology (RFE) targeting the low and ultra-low ends of the RFE spectrum (ulRFE®). This technology aims to offer safe and effective treatments for conditions like glioblastoma and diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The company is preparing for pivotal Phase III trials with its A1A treatment, which emulates the action of the chemotherapy agent paclitaxel. EMulate has also applied to the FDA for humanitarian device exemption (HDE) to treat DMG patients in the U.S. and is advancing research in pain management and mental health. Additionally, positive results have been observed in animal health and bio-agriculture models. EMulate licenses its technology to Hapbee Technologies, Inc., a consumer wellness-wearable company, of which EMulate is the largest independent shareholder.
About our ulRFE Device
EMulate’s investigational medical device is a non-invasive, non-thermal, and non-ionizing portable system using low to ultra-low frequency (DC-22kHz) electromagnetic fields to produce specific biological effects. These include increasing tubulin polymerization in cancer models, mimicking psychedelic drug effects in mental health models, and reducing pain. The device emits a low power magnetic field (< 100 mG) and can be used locally or globally, with signals stored as WAV files and delivered via an attached antenna unit.
